Metabolic approaches to cancer prioritize understanding the mechanisms and metabolic pathways implicated in cancer progression. All cancers share some marked similarities, and a major one is the ability to switch energy sources through complex adaptation, altering the body’s overall oncometabolites, which are found in higher quantities in tumor cells compared to normal cells (Nowicki & Gottlieb, 2015). Oncometabolites are metabolites that abnormally accumulate in the body due to dysfunctions in metabolic pathways. 

The Discovery of Oncometabolites

The term "oncometabolite" became notable in 2011 when a specific molecule called D-2-hydroxyglutarate (D2HG) was discovered. This molecule, derived from a natural part of cell metabolism (α-ketoglutarate), is found in unusually high levels in cancer cells but rarely in healthy cells. Researchers connected these elevated levels to mutations in the IDH1 and IDH2 genes, commonly seen in gliomas (a type of brain tumor) and certain blood cancers like acute myelogenous leukemia (AML). These high D2HG levels were found to disrupt normal cellular processes, such as DNA modification and protein control, which further drive cancer development. Since then, scientists have identified other oncometabolites—like lactate, succinate, and fumarate—that serve as potential biomarkers for tracking cancer or studying its behavior.

How Oncometabolites Are Targeted in Cancer Research

Understanding oncometabolites has opened the door to new approaches in cancer research and treatment. These unique molecules allow scientists to identify cancers using blood, urine, and tissue samples, giving them a noninvasive way to detect and monitor cancer. Oncometabolites also give insight into cancer’s genetic and metabolic behavior, which helps researchers develop targeted therapies. For example, drugs are being designed to block the harmful effects of D2HG by targeting the mutated genes that produce it (like IDH1). Additionally, other molecules, such as glycolysis inhibitors, are being studied to slow the rapid energy production cancer cells rely on. Even amino acids, such as glutamine, which cancer cells need for growth, are being targeted with therapies like DON (6-diazo-5-oxo-L-norleucine) to stop tumor progression.

The Versatility of Cancer Cells: How Tumors Adapt to Survive

Cancer, a collective term for diseases characterized by uncontrolled cell growth, exhibits remarkable complexity and adaptability. Among its many traits, a key similarity across different cancer types is their ability to reprogram energy metabolism. This metabolic flexibility allows cancer cells to thrive in diverse and often hostile environments, ensuring survival and proliferation. Oncometabolites are part of a positive feedback loop into cancer progression, with disruptions in the Krebs cycle caused by cancer cells, in turn creates more DNA damage. This occurs because oncometabolites disrupt histone demethylation, and subsequent repair factors are not recruited to DNA sites. 

The Role of Metabolism in Cancer Cell Survival

Normal cells primarily generate energy through a process known as oxidative phosphorylation, which occurs in the mitochondria and uses oxygen to convert nutrients into energy. However, cancer cells often switch to a different mode of energy production called aerobic glycolysis—or the "Warburg effect"—even in the presence of sufficient oxygen. This process breaks down glucose into lactic acid and provides energy rapidly, albeit less efficiently. Why do cancer cells adopt this seemingly wasteful metabolic pathway? The answer lies in their unique needs. Aerobic glycolysis supports the biosynthesis of essential macromolecules required for rapid cell division, such as nucleotides, lipids, and amino acids. Additionally, it creates an acidic tumor microenvironment, which helps evade the immune system and facilitates tissue invasion (12).

Cancer cells are not confined to aerobic glycolysis alone; they can adapt their energy sources based on environmental conditions. For instance, when glucose is scarce, cancer cells may switch to alternative energy sources like glutamine, fatty acids, or amino acids. This metabolic flexibility enhances their survival under nutrient-deprived or oxygen-deficient conditions—common features of solid tumors. For example, cancers like glioblastomas and pancreatic tumors rely heavily on glutamine, an amino acid that supports energy production and neutralizes oxidative stress. Similarly, prostate cancers often exploit fatty acids as an energy source, especially during metastasis (11).

The top oncometabolites implicated in cancer are:

• Fumarate
• Succinate
• Lactate

(Baryła et al, 2022).

Hypoxia and Tumor Adaptation 

Cancers growing in dense cellular regions often experience hypoxia (low oxygen levels). To counter this, cancer cells increase the expression of hypoxia-inducible factors (HIFs), which reprogram energy metabolism to optimize survival. Under hypoxic conditions, HIFs stimulate glycolysis and inhibit oxidative phosphorylation, ensuring energy production while conserving oxygen. HIFs also promote angiogenesis—the formation of new blood vessels—to restore oxygen and nutrient supply to the tumor. This contributes to cancer progression and metastasis (10).

Implications for Cancer Treatment

The ability of cancer cells to switch energy sources presents both challenges and opportunities for treatment. Targeting metabolic pathways has emerged as a promising therapeutic approach. Drugs that inhibit glycolysis (e.g., 2-deoxyglucose) or glutamine metabolism (e.g., CB-839) are under investigation for their potential to starve cancer cells of necessary resources. However, the adaptability of cancer metabolism means that single-target therapies may not be sufficient. Combining metabolic inhibitors with other therapies, such as immunotherapy, may yield better results.

Despite the diversity of cancers in origin and progression, their shared ability to adapt metabolically underscores a fundamental mechanism for survival and malignancy. Whether through aerobic glycolysis, alternative nutrient uptake, or hypoxic adaptation, cancer cells demonstrate an extraordinary capacity for energy innovation. Recognizing these patterns not only aids in understanding cancer biology but also provides critical insights for developing effective treatments. Cancer’s adaptability is a defining feature that makes it particularly challenging to treat, but understanding this trait also holds the key to combating it. By targeting the metabolic rewiring of cancer cells, researchers can exploit the very mechanisms that support tumor survival. 

A Promising Future for Oncometabolites in Cancer Treatment 

The study of oncometabolites holds great promise for revolutionizing cancer care. These molecules are not just useful for identifying cancer early; they are also paving the way for highly personalized, targeted treatments. Researchers are enthusiastic about how oncometabolites could enable faster and more precise cancer diagnoses, improving patient outcomes. Additionally, the development of new drugs targeting specific metabolic pathways could lead to less toxic and more effective treatments. With ongoing advances, the integration of oncometabolites into drug discovery and precision medicine is set to reshape how we approach cancer management.

Understanding and targeting these molecules puts us closer to limiting cancer’s growth and, possibly, eradicating it altogether. The future of cancer treatment looks brighter as science dives deeper into the role of oncometabolites

References

1. Kaushik, A. K., & DeBerardinis, R. J. (2018). Applications of metabolomics to study cancer metabolism. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1870(1), 2-14. https://doi.org/10.1016/j.bbcan.2018.06.001

2. Martinez-Reyes, I., & Chandel, N. S. (2020). Mitochondrial TCA cycle metabolites control physiology and disease. Nature Communications, 11, 102. https://doi.org/10.1038/s41467-019-13668-3

3. Intlekofer, A. M., & Finley, L. W. S. (2019). Metabolic signatures of cancer cells and their influence on tumor microenvironment. Current Opinion in Biotechnology, 64, 48-54. https://doi.org/10.1016/j.copbio.2019.10.004

4. Wang, J. H., Lei, K. F., & Han, F. (2021). Tumor-derived metabolites as immunomodulatory targets in cancer therapy. Frontiers in Immunology, 12, 658922. https://doi.org/10.3389/fimmu.2021.658922.

5. Dang, L., White, D. W., Gross, S., et al. (2019). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature Reviews Cancer, 19(7), 429-442. https://doi.org/10.1038/s41568-019-0159-y
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6732276/#mgg3873-bib-0021
7. Pavlova, N. N., & Thompson, C. B. (2016). The emerging hallmarks of cancer metabolism. Cell Metabolism, 23(1), 27-47. DOI: 10.1016/j.cmet.2015.12.006
8. Vaupel, P., Schmidberger, H., & Mayer, A. (2019). The Warburg effect reinterpreted. Advances in Experimental Medicine and Biology, 1136, 169-196. DOI: 10.1007/978-3-030-12734-3_11
9. Anderson, N. M., & Mucka, P. (2018). The emerging role and therapeutic potential of lactate as a mediator of cancer cell metabolism. Frontiers in Oncology, 8, 432. DOI: 10.3389/fonc.2018.00432
10. Semenza, G. L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell, 148(3), 399-408. DOI: 10.1016/j.cell.2012.01.021
11.  Altman, B. J., Stine, Z. E., & Dang, C. V. (2016). From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer, 16(10), 749–764. DOI: 10.1038/nrc.2016.114
12.  Warburg, O. (1956). On the Origin of Cancer Cells. Science, 123(3191), 309-314. DOI: 10.1126/science.123.3191.309
13.  Liu, Y., & Yang, C. (2021). Oncometabolites in cancer: current understanding and challenges. Cancer research, 81(11), 2820-2823.
14. Baryła M, Semeniuk-Wojtaś A, Róg L, Kraj L, Małyszko M, Stec R. Oncometabolites-A Link between Cancer Cells and Tumor Microenvironment. Biology (Basel). 2022 Feb 9;11(2):270. doi: 10.3390/biology11020270. PMID: 35205136; PMCID: PMC8869548.